Staphylococcus aureus News and Research RSS Feed - Staphylococcus aureus News and Research

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.
Personalized antibiotic therapy can help fight antibiotic-resistant infections

Personalized antibiotic therapy can help fight antibiotic-resistant infections

The Centers for Disease Control and Prevention warned last fall that the U.S. faces "potentially catastrophic consequences" if it doesn't act quickly to combat the growing threat of antibiotic-resistant infections, which kill about 23,000 Americans a year. [More]
Current sequencing protocols overlook DNA crucial to bacterial virulence

Current sequencing protocols overlook DNA crucial to bacterial virulence

Genomic sequencing is supposed to reveal the entire genetic makeup of an organism. For infectious disease specialists, the technology can be used to analyze a disease-causing bacterium to determine how much harm it is capable of causing and whether or not it will be resistant to antibiotics. [More]
Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI). [More]
Infection prevention and control guidance prioritizes strategies to combat MRSA

Infection prevention and control guidance prioritizes strategies to combat MRSA

New guidelines aim to reduce the prevalence of methicillin-resistant Staphylococcus aureus (MRSA), improve patient safety and prioritize current prevention efforts underway in hospitals. This drug resistant bacterium is a common source of patient morbidity and mortality in U.S. hospitals, causing nearly twice the number of deaths, significantly longer hospital stays and higher hospital costs than other forms of the bacteria. [More]
Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients. [More]
S. pneumoniae is major cause of severe pneumonia in Gambian children

S. pneumoniae is major cause of severe pneumonia in Gambian children

Researchers have published a detailed survey of children with pneumonia in the Gambia, which reveals that Streptococcus pneumoniae is the predominant aetiological agent and that multiple pathogens are present in at least half of cases. [More]
Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI). [More]
NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

The Medicines Company today announced the publication of the results from the SOLO I Phase 3 clinical trial of ORBACTIV (oritavancin), an investigational intravenous antibiotic treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), in the New England Journal of Medicine. [More]
New single-dose antibiotic is as effective as twice-daily infusion given for up to 10 days

New single-dose antibiotic is as effective as twice-daily infusion given for up to 10 days

In the battle against stubborn skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), a new single-dose antibiotic is as effective as a twice-daily infusion given for up to 10 days, according to a large study led by Duke Medicine researchers. [More]

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

A study published in today's New England Journal of Medicine reports that the antibiotic dalbavancin is as effective as vancomycin, the current standard-of-care antibiotic used to treat serious bacterial skin and skin-structure infections. [More]
Superbugs decrease among patients after adding UVD to cleaning regimen

Superbugs decrease among patients after adding UVD to cleaning regimen

Healthcare-associated vancomycin-resistant enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (CD), and other multidrug-resistant organisms (MDRO) were decreased among patients after adding ultraviolet environmental disinfection (UVD) to the cleaning regimen, according to a study published in the June issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC). [More]
MGH researchers test novel approach to disinfecting wounds in animal study

MGH researchers test novel approach to disinfecting wounds in animal study

Application of a technology currently used to disinfect food products may help to get around one of the most challenging problems in medicine today, the proliferation of bacteria resistant to antibiotics and other antimicrobial drugs. [More]
Disease-causing bacteria can linger in airplane cabins for days, says study

Disease-causing bacteria can linger in airplane cabins for days, says study

Disease-causing bacteria can linger on surfaces commonly found in airplane cabins for days, even up to a week, according to research presented at the annual meeting of the American Society for Microbiology. [More]
LA BioMed researcher receives APIC Award for Publication Excellence

LA BioMed researcher receives APIC Award for Publication Excellence

Loren Miller, MD, a Los Angeles Biomedical Research Institute (LA BioMed) lead researcher, is the senior author of a published study that will receive the Association for Professionals in Infection Control and Epidemiology (APIC) Award for Publication Excellence at its annual conference in Anaheim on June 7. [More]
Study: E-cigarettes appear to increase virulence of drug- resistant and life-threatening bacteria

Study: E-cigarettes appear to increase virulence of drug- resistant and life-threatening bacteria

Despite being touted by their manufacturers as a healthy alternative to cigarettes, e-cigarettes appear in a laboratory study to increase the virulence of drug- resistant and potentially life-threatening bacteria, while decreasing the ability of human cells to kill these bacteria [More]
New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

With rates of Clostridium difficile (C. difficile) now rivaling drug-resistant Methicillin-resistant Staphylococcus aureus (MRSA) as the most common bacteria to cause healthcare-associated infections, new expert guidance encourages healthcare institutions to implement and prioritize prevention efforts for this infectious diarrhea. [More]
Researchers identify novel vancomycin-resistant MRSA superbug in Brazil

Researchers identify novel vancomycin-resistant MRSA superbug in Brazil

An international research team led by Cesar A. Arias, M.D., Ph.D., at The University of Texas Health Science Center at Houston has identified a new superbug that caused a bloodstream infection in a Brazilian patient. The report appeared in the April 17 issue of The New England Journal of Medicine. [More]
Scientists report new approach to restore penicillin's combat effectiveness against bacterial infections

Scientists report new approach to restore penicillin's combat effectiveness against bacterial infections

Penicillin, one of the scientific marvels of the 20th century, is currently losing a lot of battles it once won against bacterial infections. But scientists at the University of South Carolina have just reported a new approach to restoring its combat effectiveness, even against so-called "superbugs." [More]
Daylight Medical releases SKY 6Xi disinfection technology for mobile devices

Daylight Medical releases SKY 6Xi disinfection technology for mobile devices

Daylight Medical, manufacturer and provider of innovative medical products, is pleased to announce its rollout of SKY 6Xi, disinfection technology for mobile devices. SKY 6Xi uses high intensity (254 nanometer wavelength) ultraviolet light in the "C" spectrum (UVC) at close proximity to thoroughly disinfect a mobile device. The unique power of SKY reduces the risk that Hospital-acquired infections (HAIs) are transmitted to patients while improving safety for healthcare workers. [More]

Scientists discover promising agents to fight antibiotic-resistant bacteria

In the fight against "superbugs," scientists have discovered a class of agents that can make some of the most notorious strains vulnerable to the same antibiotics that they once handily shrugged off. The report on the promising agents called metallopolymers appears in the Journal of the American Chemical Society. [More]